“We may be just days from learning whether a pending Medicare rule will provide relief from pharmacy direct and indirect remuneration (DIR) fees, and thus live up to the vision of ‘American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs,’” writes NACDS President & CEO Steven C. Anderson, IOM, CAE, in a post on Medium today.
KEY FACTS
- The opinion piece describes a four-part sequence by which DIR fee relief will save money for patients and for the government alike.
- NACDS cites research that makes a compelling case for DIR fee relief – including that related to medication adherence, or patients’ taking medications as prescribed.
- Graphical representations of the case for DIR fee reform accompany the Medium post.
